ECLIPSYS
LIVE

Serial Number

97409708

Owner

Amphista Therapeutics Limited

Attorney

Rob LeBlanc

Filing Date

May 13, 2022

Add to watchlist:

No watchlists yet
View on USPTO

ECLIPSYS Trademark

Serial Number: 97409708 • Registration: 7179544

ECLIPSYS is a trademark filed by Amphista Therapeutics Limited on May 13, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Amphista Therapeutics Limited (5 trademarks)

Bahnhofstrasse 52
Zurich CH-8001 , CH

Entity Type: 11

Trademark Details

Filing Date

May 13, 2022

Registration Date

October 3, 2023

Published for Opposition

July 18, 2023

Goods & Services

Pharmaceuticals, medicinal and veterinary preparations for the diagnosis and treatment of damaged tissue, dermatological diseases and disorders, infectious diseases, pain, obesity, cognitive disorders, inflammation, viral diseases and disorders, neurological diseases and disorders, endocrine diseases and disorders, metabolic diseases and disorders, genitourinary diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, respiratory diseases and disorders, hepatological diseases and disorders, gastrointestinal diseases and disorders, psychiatric diseases and disorders and immune system diseases and disorders; diagnostic preparations for medical and veterinary use; medicines and biotechnological preparations for medical use for the diagnosis and treatment of damaged tissue, dermatological diseases and disorders, infectious diseases, pain, obesity, cognitive disorders, inflammation, viral diseases and disorders, neurological diseases and disorders, endocrine diseases and disorders, metabolic diseases and disorders, genitourinary diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, respiratory diseases and disorders, hepatological diseases and disorders, gastrointestinal diseases and disorders, psychiatric diseases and disorders and immune system diseases and disorders; biological and chemical reagents for medical use; pharmaceutical drugs for medical purposes for the diagnosis and treatment of damaged tissue, dermatological diseases and disorders, infectious diseases, pain, obesity, cognitive disorders, inflammation, viral diseases and disorders, neurological diseases and disorders, endocrine diseases and disorders, metabolic diseases and disorders, genitourinary diseases and disorders, musculoskeletal diseases and disorders, cardiovascular diseases and disorders, cardiopulmonary diseases and disorders, oncological diseases and disorders, respiratory diseases and disorders, hepatological diseases and disorders, gastrointestinal diseases and disorders, psychiatric diseases and disorders and immune system diseases and disorders; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; none of the aforesaid goods being for the treatment and care of wounds and none of the aforesaid relating to reagents and chemicals for use in relation to biochemicals, oligonucleotides, oligonucleotide conjugates, DNA primers, DNA, genetic, and oligonucleotide probes, and quenchers

Chemicals for use in science; chemical compositions and agents for use in science; chemical preparations for use in the manufacture of pharmaceutical drugs; biological preparations for use in science; chemicals for biotechnological manufacturing processes; diagnostic preparations used for scientific or research use; reagents used for scientific or research use; proteins in raw material form for scientific or research use; none of the aforesaid relating to reagents and chemicals for use in relation to biochemicals, oligonucleotides, oligonucleotide conjugates, DNA primers, DNA, genetic, and oligonucleotide probes, and quenchers

Scientific and technological services, namely, scientific analysis, testing, engineering, development, research, and design in the field of drug discovery and the identification and development of pharmaceutical and medicinal preparations; consultancy relating to product research and development in the field of pharmaceutical and medicinal preparations for therapeutic use; research and development in the field of medical diagnostics; biotechnological and chemical testing; research and development in the pharmaceutical, chemical and biotechnological fields; research and development in the field of medicinal preparations; drug discovery services; development of pharmaceutical preparations and medicines; pharmaceutical drug development services; none of the aforesaid relating to reagents and chemicals for use in relation to biochemicals, oligonucleotides, oligonucleotide conjugates, DNA primers, DNA, genetic, and oligonucleotide probes, and quenchers

Filing History

TEAS CHANGE OF CORRESPONDENCE RECEIVED
Apr 22, 2025 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Apr 22, 2025 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Apr 22, 2025 REAP
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Apr 22, 2025 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Apr 22, 2025 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 3, 2023 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 3, 2023 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 18, 2023 NPUB
PUBLISHED FOR OPPOSITION
Jul 18, 2023 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 28, 2023 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 12, 2023 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 1, 2023 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 31, 2023 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 31, 2023 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 3, 2023 GNRN
NON-FINAL ACTION E-MAILED
Mar 3, 2023 GNRT
NON-FINAL ACTION WRITTEN
Mar 3, 2023 CNRT
ASSIGNED TO EXAMINER
Mar 2, 2023 DOCK
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 15, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 15, 2023 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 15, 2023 COAR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Feb 14, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Feb 14, 2023 TCCA
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Feb 14, 2023 ECDR
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Feb 14, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Feb 14, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Feb 14, 2023 COAR
TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Jun 2, 2022 TAEA
TEAS VOLUNTARY AMENDMENT RECEIVED
Jun 2, 2022 PARI
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
May 18, 2022 NWOS
NEW APPLICATION ENTERED
May 17, 2022 NWAP